Impact of local vaccine subsidization programs on the prevention of mumps in Japan.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
02 11 2021
Historique:
pubmed: 7 10 2021
medline: 27 1 2022
entrez: 6 10 2021
Statut: ppublish

Résumé

In Japan, although a mumps vaccination is outside the national universal vaccination program, some local governments have implemented their own program. However, little is known regarding the implementation status and the impact of these programs. In this study, we investigated the impact on the prevention of mumps, after identification of the status of the local government subsidization programs. We identified the implementation status of the subsidization programs using the websites of local governments. We retrieved the number of reported mumps cases from designated sentinel sites through the Surveillance of Infectious Diseases System implemented according to the Infectious Disease Control Law. Using this data, the impact of the subsidization program on prevention of mumps was assessed by comparing the number of mumps cases per site during the 2015-2016 outbreak among the areas categorized by the subsidization status, using a Poisson regression model. As of 2019, 26.2% (456/1,739) of the local governments were considered as having subsidization programs. We retrieved 52,719 mumps cases from 2010 to 2019. The number of mumps cases per sentinel site tended to be low in areas implementing a subsidization program, compared with the no-implementation areas throughout the data collection period. The adjusted model confirmed that the subsidization program implemented between 2010 and 2015 impacted on the number of mumps cases during the 2015-2016 outbreak, with a decrease in the numbers. Further studies with detailed data including vaccination coverage should be conducted.

Identifiants

pubmed: 34613858
doi: 10.1080/21645515.2021.1974797
pmc: PMC8828109
doi:

Substances chimiques

Measles-Mumps-Rubella Vaccine 0
Mumps Vaccine 0
Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4216-4224

Références

Pediatr Int. 2019 Sep;61(9):882-888
pubmed: 31211889
Int J Environ Res Public Health. 2020 Mar 05;17(5):
pubmed: 32150969
Hum Vaccin Immunother. 2021 Sep 2;17(9):3153-3155
pubmed: 33877956
Epidemiol Rev. 1993;15(2):265-302
pubmed: 8174658
Hum Vaccin Immunother. 2021 Jan 2;17(1):205-210
pubmed: 32530735
Lancet. 2008 Mar 15;371(9616):932-44
pubmed: 18342688
Hum Vaccin Immunother. 2021 May 4;17(5):1313-1316
pubmed: 33121326
Jpn J Infect Dis. 2019 Mar 25;72(2):106-111
pubmed: 30381683
Lancet. 1990 Mar 17;335(8690):641-5
pubmed: 1969023

Auteurs

Makoto Miyazaki (M)

Laboratory of Clinical Pharmacy, Tohoku University Graduate School of Pharmaceutical Sciences, Miyagi, Japan.

Taku Obara (T)

Department of Pharmaceutical Sciences, Tohoku University Hospital, Miyagi, Japan.
Division of Preventive Medicine and Epidemiology, Tohoku University Tohoku Medical Megabank Organization, Miyagi, Japan.

Nariyasu Mano (N)

Laboratory of Clinical Pharmacy, Tohoku University Graduate School of Pharmaceutical Sciences, Miyagi, Japan.
Department of Pharmaceutical Sciences, Tohoku University Hospital, Miyagi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH